Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03880266 · ClinicalTrials.gov registry record · Phase 2
A Study of Glycopyrronium Cloth, 2.4% in Patients With Palmar Hyperhidrosis
A Phase 2 study, sponsored by Journey Medical Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
NCT03880266: Completed Phase 2 study, sponsored by Journey Medical Corporation.
NCT03880266 is a Phase 2 study that has completed, run by Journey Medical Corporation. The registered enrollment target is 72 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (46% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03880266, a Phase 2 study, has completed, sponsored by Journey Medical Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
Study Summary
The objective of this study is to assess the efficacy and safety of glycopyrronium cloth, 2.4% when used to treat palmar hyperhidrosis.
Primary Outcome
The Hand Sweat Severity Score is a patient reported outcome, designed to measure the severity of palmar hyperhidrosis \[score on a scale from 0 (better) -10 (worse)\].
Interventions
- DRUG Vehicle
- DRUG Glycopyrronium cloth, 2.4%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2019-02-22 |
| Est. Completion | 2019-05-24 |
| Phase | Phase 2 |
What the finished NCT03880266 record still lists
NCT03880266 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (46% lower).
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT03880266 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03880266 about?
NCT03880266 is a clinical study titled "A Study of Glycopyrronium Cloth, 2.4% in Patients With Palmar Hyperhidrosis". The objective of this study is to assess the efficacy and safety of glycopyrronium cloth, 2.4% when used to treat palmar hyperhidrosis.
What is the current status of trial NCT03880266?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2019-02-22. Estimated completion is 2019-05-24.
What interventions are being tested in trial NCT03880266?
The interventions under investigation include: Vehicle (DRUG), Glycopyrronium cloth, 2.4% (DRUG).
Who is sponsoring clinical trial NCT03880266?
This trial is sponsored by Journey Medical Corporation, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03880266's enrollment target sits among peer trials
72 925th of 2000 higher than 1,065 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI